Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 14,419	$ 7,886	$ 46,699	$ 23,421
General and administrative	4,539	2,593	14,712	9,033
Total operating expenses	18,958	10,479	61,411	32,454
Loss from operations	(18,958)	(10,479)	(61,411)	(32,454)
Other income (expense), net:
Interest income	4,843	269	10,120	321
Change in fair value of contingent value right liability	0	0	(1,500)	0
Change in fair value of derivative liability	0	(5,940)	0	(3,450)
Other expense	13	0	8	0
Total other income (expense), net	4,856	(5,671)	8,628	(3,129)
Loss before income taxes	(14,102)	(16,150)	(52,783)	(35,583)
Income tax expense	(20)	0	(67)	0
Net loss and comprehensive loss	(14,122)	(16,150)	(52,850)	(35,583)
Net loss attributable to common stockholders-basic	(14,122)	(16,150)	(52,850)	(35,583)
Net loss attributable to common stockholders-diluted	$ (14,122)	$ (16,150)	$ (52,850)	$ (35,583)
Weighted-average common shares outstanding-basic	24,316,817	960,317	21,605,202	943,058
Weighted-average common shares outstanding-diluted	24,316,817	960,317	21,605,202	943,058
Net loss per share attributable to common stockholders-basic	$ (0.58)	$ (16.82)	$ (2.45)	$ (37.73)
Net loss per share attributable to common stockholders-diluted	$ (0.58)	$ (16.82)	$ (2.45)	$ (37.73)